Research programme: coagulation disorder therapeutic proteins - Sesen Bio

Drug Profile

Research programme: coagulation disorder therapeutic proteins - Sesen Bio

Latest Information Update: 18 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eleven Biotherapeutics
  • Class Proteins
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Blood coagulation disorders

Most Recent Events

  • 16 May 2018 Eleven Biotherapeutics is now called Sesen Bio
  • 12 Dec 2012 Discontinued - Preclinical for Coagulation disorders in USA (unspecified route)
  • 17 Feb 2010 Preclinical trials in Coagulation disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top